Response to letter to the Editor

Robert H. Dworkin; Alec B. O'Connor; Joel Kent; Sean C. Mackey; Srinivasa N. Raja; Brett R. Stacey; Robert M. Levy; Miroslav Backonja; Ralf Baron; Henning Harke; John D. Loeser; Rolf Detlef Treede; Dennis C. Turk; Christopher D. Wells

doi:10.1016/j.pain.2014.01.029

Response to letter to the Editor

Robert H. Dworkin, Alec B. O'Connor, Joel Kent, Sean C. Mackey, Srinivasa N. Raja, Brett R. Stacey, Robert M. Levy, Miroslav Backonja, Ralf Baron, Henning Harke, John D. Loeser, Rolf Detlef Treede, Dennis C. Turk, Christopher D. Wells

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	1045-1046
Number of pages	2
Journal	Pain
Volume	155
Issue number	5
DOIs	https://doi.org/10.1016/j.pain.2014.01.029
State	Published - May 2014
Externally published	Yes

ASJC Scopus subject areas

Neurology
Clinical Neurology
Anesthesiology and Pain Medicine

Access to Document

10.1016/j.pain.2014.01.029

Cite this

@article{c1fba865df944dabbae6ca0fcc8b4a89,

title = "Response to letter to the Editor",

author = "Dworkin, {Robert H.} and O'Connor, {Alec B.} and Joel Kent and Mackey, {Sean C.} and Raja, {Srinivasa N.} and Stacey, {Brett R.} and Levy, {Robert M.} and Miroslav Backonja and Ralf Baron and Henning Harke and Loeser, {John D.} and Treede, {Rolf Detlef} and Turk, {Dennis C.} and Wells, {Christopher D.}",

note = "Funding Information: R.H.D. has received, in the past 12 months, research grants from the US Food and Drug Administration and the US National Institutes of Health, and compensation for activities involving clinical trial research methods from Acorda, Anika, Avanir, Bayer, Charleston, Concert, DePuy, Flexion, Genentech, Johnson & Johnson, Lilly, Lpath, Nektar, Neura, Olatec, Omeros, PeriphaGen, Pfizer, Phosphagenics, Prolong, Q-Med, Regenesis, Sanofi, Spinifex, Takeda, Taris, and Teva; S.N.R. has received research support or consulting fees from Allergan, Alpharma, Medtronic, Pfizer, QRxPharma, and Schering-Plough; B.R.S. has received research support or consulting fees in the past year from Boston Scientific, Pfizer, and XenoPort; R.M.L. has received research support, consulting fees, or honoraria in the past year from Bioness, Codman, Medtronic Neurological, Northstar Neuroscience, St. Jude Neuromodulation, and Stryker; R.B. is a member of the Innovative Medicines Initiative Europain and has received research support, consulting fees, or honoraria from Allergan, Astellas, AstraZeneca, Bayer-Schering, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Desitin, Eisai, Genzyme, Gr{\"u}nenthal, Lilly, Medtronic, Mundipharma, Novartis, Pfizer, Sanofi Pasteur, Teva, and UCB Biosciences; H.H. has received research support in the past year from Astellas; J.D.L. has received consulting fees in the past year from Biodelivery Sciences, Johnson & Johnson, Medtronic, and XenoPort; R.D.T. has received research support, consulting fees, or honoraria in the past year from Astellas, AWD Pharma, Boehringer Ingelheim, Dr. Kade, GlaxoSmithKline, Gr{\"u}nenthal, and Pfizer; D.C.T. has received research support, consulting fees, or honoraria in the past year from Lilly, Mallinckrodt, Nektar, Orexo, Pfizer, Ortho-McNeil Janssen, and Xydnia; C.D.W. has received consulting and speakers{\textquoteright} fees from Astellas and Gr{\"u}nenthal; A.B.O., J.K., M.B., and S.C.M. have no financial disclosures to report.",

year = "2014",

month = may,

doi = "10.1016/j.pain.2014.01.029",

language = "English (US)",

volume = "155",

pages = "1045--1046",

journal = "Pain",

issn = "0304-3959",

publisher = "Elsevier",

number = "5",

}

TY - JOUR

T1 - Response to letter to the Editor

AU - Dworkin, Robert H.

AU - O'Connor, Alec B.

AU - Kent, Joel

AU - Mackey, Sean C.

AU - Raja, Srinivasa N.

AU - Stacey, Brett R.

AU - Levy, Robert M.

AU - Backonja, Miroslav

AU - Baron, Ralf

AU - Harke, Henning

AU - Loeser, John D.

AU - Treede, Rolf Detlef

AU - Turk, Dennis C.

AU - Wells, Christopher D.

N1 - Funding Information: R.H.D. has received, in the past 12 months, research grants from the US Food and Drug Administration and the US National Institutes of Health, and compensation for activities involving clinical trial research methods from Acorda, Anika, Avanir, Bayer, Charleston, Concert, DePuy, Flexion, Genentech, Johnson & Johnson, Lilly, Lpath, Nektar, Neura, Olatec, Omeros, PeriphaGen, Pfizer, Phosphagenics, Prolong, Q-Med, Regenesis, Sanofi, Spinifex, Takeda, Taris, and Teva; S.N.R. has received research support or consulting fees from Allergan, Alpharma, Medtronic, Pfizer, QRxPharma, and Schering-Plough; B.R.S. has received research support or consulting fees in the past year from Boston Scientific, Pfizer, and XenoPort; R.M.L. has received research support, consulting fees, or honoraria in the past year from Bioness, Codman, Medtronic Neurological, Northstar Neuroscience, St. Jude Neuromodulation, and Stryker; R.B. is a member of the Innovative Medicines Initiative Europain and has received research support, consulting fees, or honoraria from Allergan, Astellas, AstraZeneca, Bayer-Schering, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Desitin, Eisai, Genzyme, Grünenthal, Lilly, Medtronic, Mundipharma, Novartis, Pfizer, Sanofi Pasteur, Teva, and UCB Biosciences; H.H. has received research support in the past year from Astellas; J.D.L. has received consulting fees in the past year from Biodelivery Sciences, Johnson & Johnson, Medtronic, and XenoPort; R.D.T. has received research support, consulting fees, or honoraria in the past year from Astellas, AWD Pharma, Boehringer Ingelheim, Dr. Kade, GlaxoSmithKline, Grünenthal, and Pfizer; D.C.T. has received research support, consulting fees, or honoraria in the past year from Lilly, Mallinckrodt, Nektar, Orexo, Pfizer, Ortho-McNeil Janssen, and Xydnia; C.D.W. has received consulting and speakers’ fees from Astellas and Grünenthal; A.B.O., J.K., M.B., and S.C.M. have no financial disclosures to report.

PY - 2014/5

Y1 - 2014/5

UR - http://www.scopus.com/inward/record.url?scp=84898599877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898599877&partnerID=8YFLogxK

U2 - 10.1016/j.pain.2014.01.029

DO - 10.1016/j.pain.2014.01.029

M3 - Letter

C2 - 24513276

AN - SCOPUS:84898599877

VL - 155

SP - 1045

EP - 1046

JO - Pain

JF - Pain

SN - 0304-3959

IS - 5

ER -

Response to letter to the Editor

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this